Gender Affirming Vaginoplasty With Tubularized Augmented Peritoneal Cap (TAPCap) Utilizing Fish Skin Xenograft (Kerecis™)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age19-99
SponsorUniversity Hospitals Cleveland Medical Center

About this trial

Bottom gender affirming surgery is one of the key steps towards aligning the physical appearance and gender identity in transgender women. This surgery not only helps in reducing gender dysphoria but also significantly improves the quality of life and psychological well-being of the patients. The basic steps of bottom surgery typically involve the creation of a vagina using the skin from genital organs like the testes and penis, construction of the clitoris and labia. This complex surgery aims to create a functional and aesthetically pleasing vaginal canal that allows for sexual activity, urinary function, and a natural appearance.

As part of routine care, a special graft (skin-like material) called Kerecis™ is used to line the middle part of the vagina. It is made from North Atlantic cod skin that is treated in the laboratory and made suitable for surgery purposes. It can be used instead of skin. This graft has been given permission by the Food and Drug Administration (FDA) for marketing the US.

This study aims to identify changes in healing parameters following Kerecis™ based vaginoplasty. Up to 20 participants for this study.

Participants will be asked to fill out study questionnaires during follow-up visits at post-op week 2, week 12, month , and year 1.

At the 6 month post-op follow up, punch biopsies will be obtained from the deepest part, middle part, and the vaginal part most near to the vaginal opening parts to check the healing process using a microscope. The punch biopsies will be 1/8th inch x 1/8th inch each.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 19-99

Transgender women planning for gender affirming robotic vaginoplasty with TAPCap technique

Disqualifiers

Patients requiring Kerecis for Revision Vaginoplasty

Surgery candidates having Zero depth vaginoplaty (ZDV)

Non-Gender Affirming Vaginoplasty

Cases requiring the utilization of off-the-shelf grafts other than Kerecis

Trial population

Individuals requiring graft-based vaginoplasty

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Tubularized augmented peritoneal cap vaginoplasty

    Procedure/Surgery

    In this surgery, the distal portion of the neovagina is constructed using inverted penile skin, the proximal portion is made of peritoneal tissue. The area in between peritoneal tissue and penile skin is lined with the Kerecis graft in this standard of care surgery.

  • Biopsy

    Procedure/Surgery

    Biopsies will be obtained at 6 months post-op from the distal, middle, and proximal portions of the neovagina.

Treatment groups

20 Participants
are divided into 1 treatment group
Group A: Individuals receiving vaginoplasty2 interventions

Trial outcomes

Primary outcomes

1

Degree of Neovaginal Epithelialization

Degree of epithelialization of each sample biopsy. Biopsies are obtained from the proximal segment (peritoneal portion), middle segment (Xenograft portion), and, distal segment (penile skin portion) of the neovagina. Grade 0: No epithelialization Grade 1 : Minimal epithelialization Grade 2: Moderate epithelialization Grade 3: Significant epithelialization

Time frame
Six months post-op
2

Change in Vaginal Diameter

The participants' vaginal diameter is calculated based on the largest tolerated vaginal dilator size (Soul Source; CA, USA) . Measurements are reported in centimeters (cm).

Time frame
Post-op week 2, week, 12, month 6, and year 1
3

Change in Vaginal Depth

The participants' vaginal depth are calculated based on the largest tolerated vaginal dilator (Soul Source, CA, USA). Measurements are reported in centimeters (cm).

Time frame
Post-op week 2, week, 12, month 6, and year 1
4

Change in quality of life as measured by the Short-Form 36 (SF-36)

This is a validated questionnaire measuring health-related quality of life through eight domains, covering physical and mental well-being. It's widely used in healthcare to assess overall health perception and functional status. With higher scores indicating greater quality of life.

Time frame
Week 2, Week 12, Month 6, and year 1 post-op

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.